Fox Chase Cancer Center
2019 1st Line Systemic Therapy for Metastatic Urothelial Carcinoma: Cisplatin as SoC, Pembro Mono as Alternative for Cis-Ineligible, Chemo +/- Atezolizumab vs. Atezolizumab Alone, Enfortumab Vedotin + Pembro, and Subsequent Therapies
Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA
Dr. Plimack is a ...
read more ↘
Dr. Plimack is a ...
read more ↘
Comments 1
Login to view comments.
Click here to Login
